- Home
- SKYE
as 04-18-2025 1:43pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 80.7M | IPO Year: | N/A |
| Target Price: | $16.60 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $17.65 | Next Earning Date: | 05-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
GlobeNewswire
5 days ago
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
GlobeNewswire
a month ago
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
GlobeNewswire
2 months ago
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Skye Bioscience to Participate in SXSW Session on Obesity
Simply Wall St.
2 months ago
We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely
GlobeNewswire
2 months ago
Skye Bioscience to Present at TD Cowen Health Care Conference
Compare SKYE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.